Prof. Jiaping Zheng 郑家平
Chief Physician, Professor
Department of Interventional Radiology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Non-surgical comprehensive treatment of liver, gallbladder, and pancreatic tumors; salvage therapy for refractory tumors; minimally invasive interventional techniques including iodine-125 seed implantation and tumor ablation.
Dr. Zheng holds a medical doctorate and serves as Chief Physician and Professor at Zhejiang Chinese Medical University. Dr. Zheng is a graduate supervisor at Wenzhou Medical University and Deputy Director (presiding) of the Interventional Department and Director of the Interventional Ward at the Cancer Hospital of the University of Chinese Academy of Sciences.
Professional roles
- Member, Zhejiang Branch of Chinese Medical Association
- National Standing Committee Member, Integrated Traditional Chinese and Western Medicine Professional Committee, National Tumor Minimally Invasive Alliance
- Member, Particle Group of Tumor Minimally Invasive Treatment Professional Committee, China Anti-Cancer Association
- Reviewer for Hepatology Research and Clinical Translational Oncology
Name order: in Chinese the family name comes first (Zheng Jiaping). Papers usually list the name as Jiaping Zheng or Zheng J.
Selected publications
40 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mikrochim Acta, 2025 (senior author): Monitoring miR-29a for targeted therapy of cholangiocarcinoma based on a photoelectric sensor. PubMed 40810868
- Clin Med Insights Oncol, 2024 (senior author): MiR-339-5p Inhibits Ferroptosis by Promoting Autophagic Degradation of FTH1 Through Targeting ATG7 in Liver Cancer Cells. PubMed 38628842
- Ann Transl Med, 2022 (senior author): An N(6)-methyladenosine-associated lncRNA signature for predicting clinical outcome and therapeutic responses in hepatocellular carcinoma. PubMed 35571429
- Front Oncol, 2021 (senior author): The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study. PubMed 34988019
- Biomed Pharmacother, 2019 (first author): (125)I suppressed the Warburg effect viaregulating miR-338/PFKL axis in hepatocellular carcinoma. PubMed 31514072
- Zhonghua Zhong Liu Za Zhi, 2009 (first author): [Feasibility study on CT guided percutaneous incisional needle biopsy for deep pelvic masses by different puncture approaches]. PubMed 20021836
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion